Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.
What happened
FDA inspected the clinical site from June 26 to July 15, 2025, under its Bioresearch Monitoring Program and reviewed the inspection report, documents, and the investigator’s August 4, 2025 response. FDA found that a subject was simultaneously enrolled and randomized in another clinical investigation and received that study’s investigational drug while enrolled in the cited protocol, contrary to the protocol’s exclusion and prohibited-product requirements. FDA also found drug-accountability discrepancies for six subjects between self-reported doses, site records, electronic data capture records, and the physical condition of returned kits.
What FDA found
The investigator failed to ensure the study was conducted according to the investigational plan because a subject was enrolled in another trial and received another investigational product during the study.
21 CFR 312.60The investigator failed to maintain adequate records of study-drug disposition, including dates, quantity, and use by subjects, with discrepancies for six subjects.
21 CFR 312.62(a)
What FDA wants
FDA asks the investigator to respond in writing within 15 business days describing actions taken to prevent similar violations and to establish procedures for any ongoing or future studies.
Who should pay attention
- clinical trial sponsors using investigator sites
- contract research organizations overseeing site compliance
- investigators and site staff responsible for drug accountability
This is a summary. Read the original letter on fda.gov.